Dose escalation phase of a phase I/II study of GTI-2501, an antisense to the R1 subunit of ribonucleotide reductase (RNR) and docetaxel in patients with metastatic hormone-refractory prostate cancer.

@article{Ko2006DoseEP,
  title={Dose escalation phase of a phase I/II study of GTI-2501, an antisense to the R1 subunit of ribonucleotide reductase (RNR) and docetaxel in patients with metastatic hormone-refractory prostate cancer.},
  author={Y. Ko and S. North and S. Berry and D. Ernst and L. Klotz and P. Murray and P. Venner},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 18\_suppl},
  pages={2078}
}
  • Y. Ko, S. North, +4 authors P. Venner
  • Published 2006
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2078 Background: GTI-2501 (GTI) is a 20-mer oligonucleotide that is complementary to the R1 subunit of the RNR mRNA. The R1 protein is overexpressed in multiple tumour cell lines. GTI displays anti-tumour activity against prostate cancer xenografts in mice as a single agent and in combination with mitoxantrone. GTI also adds to the anti-tumour efficacy of taxanes in breast cancer xenografts in mice. A Phase 1 study of a 14 day continuous infusion of GTI in patients with solid tumours showed no… Expand
Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?
A Polyethylenimine-Linoleic Acid Conjugate for Antisense Oligonucleotide Delivery